Research Square (Research Square),
Год журнала:
2023,
Номер
unknown
Опубликована: Дек. 19, 2023
Abstract
Purpose
Previous
studies
have
suggested
that
some
microRNAs
(miRNAs)
play
a
vital
role
in
carcinogenesis
and
progression
of
hepatocellular
carcinoma
(HCC).
As
one
these
newly
found
miRNAs,
miR-199a-3p
(miR199a),
has
been
shown
to
be
highly
involved
the
regulation
HCC
growth.
However,
mechanism
underlying
miR199a
remains
unclear.
Methods
In
this
study,
evaluation
expression
cells
(HCCs)
tissues
was
evaluated
by
RT-qPCR.
Bioinformatics
analysis
luciferase
reporter
assay
were
performed
prove
effect
on
SGK3.
CCK-8
assess
proliferation
HCCs
(HepG2
HuH7)
after
transfection.
Subsequently,
biological
function
miR199a/SGK3
axis
investigated.
Results
Herein,
we
is
usually
underexpressed
tissue
cell
lines
compared
with
their
corresponding
control.
The
pattern
SGK3,
as
direct
target
miR199a,
opposite
miR199a.
shRNA-mediated
silencing
SGK3
decreased
vitro
;
however,
phenotypes
promoted
mimics.
Mechanistically,
inhibited
through
downregulation
Akt/mTOR
signalling
targeting
Conclusion
our
findings
demonstrated
an
important
for
mediator
signaling
pathway.
These
highlight
potential
therapeutic
managing
HCC.
Journal of Thrombosis and Haemostasis,
Год журнала:
2023,
Номер
21(6), С. 1397 - 1408
Опубликована: Март 15, 2023
Thrombosis,
both
venous
and
arterial,
is
a
leading
cause
of
morbidity
mortality
in
patients
with
cancer.
Studies
on
the
molecular
basis
cancer-associated
thrombophilia
have
long
story
starting
from
first
observation
presence
tumor
cells
circulating
microthrombi
2
centuries
ago.
The
profound
link
between
pathways
blood
coagulation
biology
has
been
more
unraveled,
new
actors
this
complex
interaction
identified.
unfavorable
impact
thrombosis
patient
cancer,
which
also
hangs
high
bleeding
risk
as
compared
to
noncancer
population,
led
during
years
production
large
clinical
studies
adopt
best
prophylaxis
treatment
strategies
thromboembolism
different
medical
surgical
settings,
now
incorporated
dedicated
international
guidelines.
This
field,
however,
still
represents
an
open
challenge
due
intrinsic
variability
cancer
his/her
personal
history
cardiovascular
factors,
well
type,
site
stage
tumor,
use
wide
array
sophisticated
anticancer
drugs.
review
aims
highlight
some
many
key
observations
field
thrombosis,
spanning
scope
fundamental
advanced
trials
anticoagulants.
We
hope
that
examples
we
included
will
inspire
readers
explore
discuss
these
topics,
thereby
increasing
awareness
cancer-related
physicians
patients.
Abstract
Over
the
past
decade,
precision
medicine
has
garnered
increasing
attention,
making
significant
strides
in
discovering
new
therapeutic
drugs
and
mechanisms,
resulting
notable
achievements
symptom
alleviation,
pain
reduction,
extended
survival
rates.
However,
limited
target
specificity
of
primary
inter‐individual
differences
have
often
necessitated
high‐dosage
strategies,
leading
to
challenges
such
as
restricted
deep
tissue
penetration
rates
systemic
side
effects.
Material
science
advancements
present
a
promising
avenue
for
these
issues.
By
leveraging
distinct
internal
features
diseased
regions
application
specific
external
stimuli,
responsive
materials
can
be
tailored
achieve
targeted
delivery,
controllable
release,
biochemical
reactions.
This
review
aims
highlight
latest
stimuli‐responsive
their
potential
medicine.
Initially,
we
introduce
disease‐related
stimuli
capable
elucidating
reaction
principles
functional
groups.
Subsequently,
provide
detailed
analysis
representative
pre‐clinical
across
various
clinical
applications,
including
enhancements
treatment
cancers,
injury
diseases,
inflammatory
infection
high‐throughput
microfluidic
biosensors.
Finally,
discuss
some
challenges,
off‐target
effects,
long‐term
impacts
nano‐materials,
ethical
concerns,
offer
insights
into
future
perspectives
materials.
Biomedicines,
Год журнала:
2025,
Номер
13(4), С. 906 - 906
Опубликована: Апрель 8, 2025
According
to
the
literature,
cardiovascular
diseases
(CVDs)—including
myocardial
infarction,
stroke,
and
venous
thromboembolism
(VTE)—are
among
leading
causes
of
mortality
morbidity
worldwide.
Evidence
suggests
that
CVDs
share
common
risk
factors
pathophysiological
mechanisms.
Similar
Mosaic
Theory
Hypertension
proposed
by
Irvine
Page
in
1949,
pathophysiology
VTE
is
multifactorial,
involving
multiple
interacting
processes.
The
concept
immunothrombosis,
introduced
Engelmann
Massberg
2009,
describes
interplay
between
immune
system
thrombosis.
Both
thrombosis
hemostasis
core
mechanisms,
including
platelet
activation
fibrin
formation.
Additionally,
mediators—such
as
monocytes,
neutrophil
extracellular
traps
(NETs),
lymphocytes,
selectins,
various
molecular
factors—play
a
critical
role
thrombus
This
review
highlights
inflammation
key
factor
for
pulmonary
embolism
(APE).
Immunity
central
complex
interactions
coagulation
cascade,
platelets,
endothelium,
reactive
oxygen
species
(ROS),
genetic
factors.
Specifically,
we
examine
roles
cells,
microRNAs
(miRNAs)
APE
explore
potential
therapeutic
targets.
aims
elucidate
miRNAs
future
perspective.
Cancers,
Год журнала:
2024,
Номер
16(2), С. 458 - 458
Опубликована: Янв. 21, 2024
Many
cancer
patients
will
experience
venous
thromboembolism
(VTE)
at
some
stage,
with
the
highest
rate
in
initial
period
following
diagnosis.
Novel
therapies
may
further
enhance
risk.
VTE
a
setting
is
associated
poor
prognostic,
decreased
quality
of
life,
and
high
healthcare
costs.
If
thromboprophylaxis
hospitalized
perioperative
settings
widely
accepted
clinical
practice
supported
by
guidelines,
it
not
same
situation
ambulatory
patient
settings.
The
guidelines
do
recommend
primary
thromboprophylaxis,
except
high-risk
cases.
However,
nowadays,
risk
stratification
still
challenging,
although
many
tools
have
been
developed.
Khrorana
score
remains
most
used
method,
but
has
limits.
This
narrative
review
aims
to
present
current
relevant
knowledge
assessment
patients,
starting
from
guideline
recommendations
continuing
specific
methods
machine
learning
models
approaches.
Biomarkers,
genetic,
features
were
tested
alone
or
groups.
Old
new
are
exposed,
underlining
their
utility.
Imaging
biomolecular
approaches
screening
outpatients
also
presented,
which
could
help
decisions.
Cancers,
Год журнала:
2024,
Номер
16(9), С. 1769 - 1769
Опубликована: Май 3, 2024
The
prevention
and
appropriate
management
of
venous
thromboembolism
in
cancer
patients
is
paramount
importance.
However,
the
literature
data
report
an
underestimation
this
major
problem
with
gynecological
cancers,
inconsistent
risk
assessment
prophylaxis
patient
setting.
This
narrative
review
provides
a
comprehensive
overview
available
evidence
regarding
patients,
focusing
on
specific
context
tumors,
exploring
discussing
factors,
assessment,
pharmacological
prophylaxis.
We
found
that
current
understanding
malignancy
largely
based
studies
solid
cancers
general.
Hence,
further,
larger,
well-designed
research
area
needed.
Journal of Leukocyte Biology,
Год журнала:
2024,
Номер
unknown
Опубликована: Окт. 25, 2024
Neutrophil
extracellular
traps
(NETs)
are
promising
promoters
in
venous
thromboembolism
(VTE).
In
the
present
study,
we
have
investigated
potential
thrombogenic
role
of
NETs
colorectal
cancer
(CRC).
A
total
583
patients
with
gastrointestinal
malignancies
who
were
diagnosed
or
without
VTE
by
extremities
arteriovenous
ultrasound
and
computed
tomography
enrolled.
The
incidence
CRC
was
as
high
17.53%.
serological
ELISA
experiments,
Cit-H3,
MPO
cfDNA
significantly
overexpressed
compared
to
healthy
individuals.
Neutrophils
from
produced
appreciable
amounts
after
stimulation
phorbol-12-myristate-13-acetate,
which
lacking
CfDNA
positively
correlated
plasmin-α2-antiplasmin
complex
tissue
plasmin
activator
inhibitor-1
complex,
Cit-H3
suggesting
that
associated
increased
fibrinolytic
activity.
We
screened
some
NETs-related
genes
analysing
several
high-throughput
sequencing
datasets
NETs.
FCGR1A
identified
optimal
target
gene
pan-cancer
expression
analysis
survival
analysis.
peripheral
blood
individuals
showed
a
positive
correlation
cfDNA.
Neutrophil-derived
reduced
inhibitor
exposure.
These
findings
indicate
actively
involved
CRC.
thrombotic
marker
therapeutic
prevent
consequences
cancer.
